Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

20171,123 citationsJournal Articlebronze Open Access

Authors

Charles V. Pollack · Heidelberg University

Paul Reilly · Boehringer Ingelheim (Germany)

Joanne van Ryn · University Hospital Heidelberg

John W. Eikelboom · Thrombosis and Atherosclerosis Research Institute

Stephan Glund · Heidelberg University

Richard A. Bernstein · Heidelberg University

Robert Dubiel

Abstract

In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947 .).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Heparin-Induced Thrombocytopenia and Thrombosis Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 5, pp. 431-441

DOI: 10.1056/nejmoa1707278

Field-Weighted Citation Impact: 102.05